Basics TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases. IPO Date: June 1, 2010 Sector: Healthcare Industry: Biotech Market Cap: $4.88B Activated in VL: True Average Daily Range Avg Daily Range: $0.46 | 3.14% Avg Daily Range (30 D): $0.71 | 2.17% Avg Daily Range (90 D): $0.57 | 1.75% Institutional Daily Volume Avg Daily Volume: 1.65M Avg Daily Volume (30 D): 1.69M Avg Daily Volume (90 D): 1.85M Trade Size Avg Trade Size (Sh.): 117 Avg Trade Size (Sh.) (30 D): 66 Avg Trade Size (Sh.) (90 D): 68 Institutional Trades Total Inst.Trades: 5,676 Avg Inst. Trade: $2.84M Avg Inst. Trade (30 D): $3.55M Avg Inst. Trade (90 D): $3.32M Avg Inst. Trade Volume: .15M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5M Avg Closing Trade (30 D): $8.69M Avg Closing Trade (90 D): $8.12M Avg Closing Volume: 263.21K     News Nov 10, 2025 @ 9:00 PM TG Therapeutics to Participate in the TD Cowen Imm... Source: Tg Therapeutics, Inc. Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A Mar 9, 2025 @ 5:19 PM Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap G... Source: Lekha Gupta Nov 29, 2024 @ 1:00 PM TG Therapeutics to Participate in the Evercore Hea... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $3.06 $2.69 $.19 Diluted EPS $2.77 $2.43 $.17 Revenue $ 531.9M $ 161.71M $ 141.15M Gross Profit $ 453.93M $ 133.62M $ 122.21M Net Income / Loss $ 447.47M $ 390.9M $ 28.19M Operating Income / Loss $ 102.78M $ 29.37M $ 34.84M Cost of Revenue $ 77.97M $ 28.09M $ 18.94M Net Cash Flow $ -121.71M $ -55.03M $ -3M PE Ratio 11.18     Splits Apr 30, 2012:   5:281 Jul 14, 2011:   1:50 Sep 25, 2003:   1:5